Corsair planning Phase 1 trial of treprostinil skin patch for PAH
Corsair Pharma successfully completed preclinical studies testing its skin patch delivery system for treprostinil as a treatment for pulmonary arterial hypertension (PAH), and is now planning to launch a Phase 1 clinical trial in the next few months. That’s according to new updates from the U.S.-based company, which…